Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Glaukos Corporation
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of iStent inject in eyes of subjects with primary open-angle glaucoma previously on two anti-glaucoma medications. Outcomes will be evaluated at 12 and 24 months.
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Diagnosed with primary open angle glaucoma (POAG)
Subject on two ocular hypotensive medications
You may not be if
Traumatic, uveitic, neovascular, or angle closure glaucoma
Fellow eye already enrolled
Clareo Health | iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications
